Key Takeaways IDXX's Q3 CAG Diagnostics recurring revenues grew over 10% organically due to U.S. and overseas gains.IDEXX expands globally with strong installed base growth and plans to enter three new countries by 2026.IDEXX faces liquidity risks and a stronger dollar, trimming margins on international sales.IDEXX Laboratories, Inc. (IDXX) is well-poised to grow in the upcoming quarters due to the strong momentum in its CAG (Companion Animal Group) Diagnostics business. The company is also growing its glob ...